Piper Sandler Assumes Ionis Pharmaceuticals at Overweight, Announces Price Target of $58
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Do Kim assumes Ionis Pharmaceuticals (NASDAQ:IONS) with an Overweight rating and announces a price target of $58.

June 07, 2023 | 8:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Do Kim assumes Ionis Pharmaceuticals with an Overweight rating and a price target of $58.
The Overweight rating and price target of $58 by Piper Sandler analyst Do Kim indicate a positive outlook for Ionis Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it suggests that the analyst believes the stock is undervalued and has potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100